Pilaniya U, Pilaniya K, Chandrawanshi H K, Gupta N, Rajput M S
VNS Institute of Pharmacy, Bhopal, India.
Pharmazie. 2011 Jan;66(1):24-30.
The present study aimed to produce verapamil hydrochloride-loaded solid lipid microparticles (SLM) by the w/o/w emulsion solvent evaporation technique, using diethyl ether as solvent phase, glyceryl monostearate as biodegradable polymer and Span 60 as surfactant. SLM of spherical shape were prepared by simple dilution of the emulsion with water. To increase the lipid load the process was conducted at 50 degrees C, and in order to reach sub-micron size, a high-shear homogenizer was used. The encapsulation efficiency of prepared SLM reached 74.29 +/- 0.76%. Particle size (98.55 +/- 1.42 microm), surface morphology (spherical) and drug loading efficiency (18.57 +/- 1.25% w/w) were investigated. And optimization of drug polymer ratio (3:1), nature and concentration of emulsion stabilizer in the external aqueous (0.1%), phase viscosity of external aqueous phase (0.5%), volume of external aqueous phase and stirring rate (1000 rpm) were detected. Analysis of microsphere content after processing showed that verapamil did not undergo any chemical modification within the micro-particles. The in-vitro release of verapamil from the microparticles was very low and an initial burst effect of 17% of the dose was observed. The slow release may help to avoid a high frequency of administration. The prepared solid lipid microparticles appear to have interesting perspectives as delivery systems for the oral administration of verapamil hydrochloride with improved half-life, improved bioavailability, and minimized local and systemic gastrointestinal disturbances of the drug.
本研究旨在通过w/o/w乳液溶剂蒸发技术制备载盐酸维拉帕米的固体脂质微粒(SLM),使用乙醚作为溶剂相,单硬脂酸甘油酯作为可生物降解聚合物,Span 60作为表面活性剂。通过用水简单稀释乳液制备球形SLM。为了增加脂质负载量,该过程在50℃下进行,并且为了达到亚微米尺寸,使用了高剪切均质器。制备的SLM的包封率达到74.29±0.76%。研究了粒径(98.55±1.42微米)、表面形态(球形)和载药效率(18.57±1.25% w/w)。并检测了药物与聚合物比例(3:1)、外部水相中乳液稳定剂的性质和浓度(0.1%)、外部水相的相粘度(0.5%)、外部水相的体积和搅拌速率(1000转/分钟)的优化情况。处理后微球含量分析表明,维拉帕米在微粒内未发生任何化学修饰。维拉帕米从微粒中的体外释放非常低,观察到初始剂量的17%有突释效应。缓慢释放可能有助于避免高给药频率。制备的固体脂质微粒作为盐酸维拉帕米口服给药的递送系统似乎具有有趣的前景,具有改善的半衰期、提高的生物利用度以及最小化药物的局部和全身胃肠道干扰。